Sección: Pequeñas soluciones para grandes problemasLas separatas son unidades de informacion muy útiles y de gran valor para los investigadores pero que, a menudo, resultan una rémora pues su materia no encaja bien en nuestra biblioteca.N

Benner, Jacqueline

Dallmann, Guido

de Zeeuw, Dick

Jankowski, Joachim

Lambers Heerspink, Hiddo J.

Mayer, Bernd

Mayer, Gert

Mischak, Harald

Oberbauer, Rainer

Pena, Michelle J.

Rossing, Peter

Woloszczuk, Wolfgang

Pena, Michelle J

Lambers Heerspink, Hiddo J

Copenhagen University Research Information System

Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes

Real Díaz, Isabel

Digital.CSIC

 1 Qué hacer con las separatas Isabel Real  bibescu@ cica.es Las separatas son unidades de informacion muy útiles y de gran valor para los investigadores pero que, a menudo, resultan una rémora pues su materia no encaja bien en nuestra biblioteca. Casi todas proceden de donaciones personales de sus autores pero no todas merecen ser catalogadas. En la Escuela de Estudios Hispanoamericanos confeccionamos  un Boletín de separatas con la fotocopia de las portadas de aquellas que no son incorporadas a nuestros fondos. De periodicidad anual, se encuentra en la sala de lectura y a disposición de los lectores. 

Qué hacer con las separatas

University of Groningen

Diabetic kidney disease occurs in similar to 25-40% of patients with type 2 diabetes. Given the high risk of progressive renal function loss and end-stage renal disease, early identification of patients with a renal risk is important. Novel biomarkers may aid in improving renal risk stratification. In this review, we first focus on the classical panel of albuminuria and estimated glomerular filtration rate as the primary clinical predictors of renal disease and then move our attention to novel biomarkers, primarily concentrating on assay-based multiple/panel biomarkers, proteomics biomarkers and metabolomics biomarkers. We focus on multiple biomarker panels since the molecular processes of renal disease progression in type 2 diabetes are heterogeneous, rendering it unlikely that a single biomarker significantly adds to clinical risk prediction. A limited number of prospective studies of multiple biomarkers address the predictive performance of novel biomarker panels in addition to the classical panel in type 2 diabetes. However, the prospective studies conducted so far have small sample sizes, are insufficiently powered and lack external validation. Adequately sized validation studies of multiple biomarker panels are thus required. There is also a paucity of studies that assess the effect of treatments on novel biomarker panels and determine whether initial treatment-induced changes in novel biomarkers predict changes in long-term renal outcomes. Such studies can not only improve our healthcare but also our understanding of the mechanisms of actions of existing and novel drugs and may yield biomarkers that can be used to monitor drug response. We conclude that this will be an area to focus research on in the future.</p

Qué hacer con las separatas

Abstract

Similar works

Full text

Available Versions

Copenhagen University Research Information System

Digital.CSIC

University of Groningen

Dissertations of the University of Groningen

Publikationsserver der RWTH Aachen University

University of Groningen

ARTS repository - University of Groningen

Proceedings - University of Groningen

RWTH Publications

Proceedings - University of Groningen